The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia

On February 22, 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product gemtuzumab ozogamicin (Mylotarg; Pfizer, New York City, NY), intended for the treatment of acute myeloid leukem...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Ali, Sahra, Dunmore, Helen‐Marie, Karres, Dominik, Hay, Justin L., Salmonsson, Tomas, Gisselbrecht, Christian, Sarac, Sinan B., Bjerrum, Ole W., Hovgaard, Doris, Barbachano, Yolanda, Nagercoil, Nithyanandan, Pignatti, Francesco
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2019
Sujets:
Regulatory Issues: EMA
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516123/
https://ncbi.nlm.nih.gov/pubmed/30898889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0025
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires